This certification represents an achievement in the Company's mission to provide innovative solutions for cancer treatment, further solidifying IQwave's commitment to improving patient outcomes.

IQwave's advanced tumour treatment technology offers a non-invasive approach to targeting and treating tumours with exceptional precision, while minimizing the impact on surrounding healthy tissue. The certification from regulatory authorities in Singapore underscores the safety, efficacy, and quality of IQwave's product, paving the way for its adoption in clinical settings across the country. When the Company decides to include Singapore in the market plan, the approval will become crucial, setting the stage for optimal conditions.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.